These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35699910)

  • 1. Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.
    Gasparyan SB; Buenconsejo J; Kowalewski EK; Oscarsson J; Bengtsson OF; Esterline R; Koch GG; Berwanger O; Kosiborod MN
    Ther Innov Regul Sci; 2022 Sep; 56(5):785-794. PubMed ID: 35699910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
    Kosiborod M; Berwanger O; Koch GG; Martinez F; Mukhtar O; Verma S; Chopra V; Javaheri A; Ambery P; Gasparyan SB; Buenconsejo J; Sjöström CD; Langkilde AM; Oscarsson J; Esterline R
    Diabetes Obes Metab; 2021 Apr; 23(4):886-896. PubMed ID: 33319454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
    Heerspink HJL; Jongs N; Schloemer P; Little DJ; Brinker M; Tasto C; Karpefors M; Wheeler DC; Bakris G; Perkovic V; Nkulikiyinka R; Rossert J; Gasparyan SB
    J Am Soc Nephrol; 2023 Dec; 34(12):2025-2038. PubMed ID: 37872654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The win ratio approach for composite endpoints: practical guidance based on previous experience.
    Redfors B; Gregson J; Crowley A; McAndrew T; Ben-Yehuda O; Stone GW; Pocock SJ
    Eur Heart J; 2020 Dec; 41(46):4391-4399. PubMed ID: 32901285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials.
    Gasparyan SB; Kowalewski EK; Folkvaljon F; Bengtsson O; Buenconsejo J; Adler J; Koch GG
    J Biopharm Stat; 2021 Nov; 31(6):765-787. PubMed ID: 34551682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The maraca plot: A novel visualization of hierarchical composite endpoints.
    Karpefors M; Lindholm D; Gasparyan SB
    Clin Trials; 2023 Feb; 20(1):84-88. PubMed ID: 36373800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
    Weir IR; Dufault SM; Phillips PPJ
    Trials; 2024 Mar; 25(1):180. PubMed ID: 38468320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
    Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
    Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
    Lawrance R; Degtyarev E; Griffiths P; Trask P; Lau H; D'Alessio D; Griebsch I; Wallenstein G; Cocks K; Rufibach K
    J Patient Rep Outcomes; 2020 Aug; 4(1):68. PubMed ID: 32833083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics.
    Seifu Y; Mt-Isa S; Duke K; Gamalo-Siebers M; Wang W; Dong G; Kolassa J
    J Biopharm Stat; 2023 Nov; 33(6):696-707. PubMed ID: 36545791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review.
    Little DJ; Gasparyan SB; Schloemer P; Jongs N; Brinker M; Karpefors M; Tasto C; Rethemeier N; Frison L; Nkulikiyinka R; Rossert J; Heerspink HJL
    J Am Soc Nephrol; 2023 Dec; 34(12):1928-1935. PubMed ID: 37807165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical models for composite endpoints of death and non-fatal events: a review.
    Mao L; Kim K
    Stat Biopharm Res; 2021; 13(3):260-269. PubMed ID: 34540133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
    Bakal JA; Westerhout CM; Armstrong PW
    Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating estimands into clinical trial statistical analysis plans.
    Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
    Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.
    Bao W; Gaffney M; Pressler ML; Fayyad R; Wisemandle W; Beckerman B; Wolski KE; Nissen SE
    Clin Trials; 2020 Oct; 17(5):535-544. PubMed ID: 32643966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components.
    Liao R; Chakladar S; Gamalo M
    Pharm Stat; 2022 Nov; 21(6):1342-1356. PubMed ID: 35766113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.